FDA issues Myfortic tablets safety alert

Nov 28, 2007

The U.S. Food and Drug Administration issued a safety alert for pregnant patients using the kidney transplant drug Myfortic delayed-release tablets.

The FDA said it has been determined the medication is associated with increased risks of pregnancy loss and congenital malformations. Officials said the pregnancy category for Myfortic has been changed to Category D -- positive evidence of fetal risk.

Myfortic is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.

The FDA said a transplant patient planning a pregnancy shouldn't use Myfortic unless she cannot be successfully treated with other immunosuppressant drugs.

Myfortic is manufactured by Novartis Pharmaceuticals.

Copyright 2007 by United Press International

Explore further: Despite broad awareness, only half of doctors use prescription drug monitoring programs

add to favorites email to friend print save as pdf

Related Stories

Evolving robot brains

1 hour ago

Researchers are using the principles of Darwinian evolution to develop robot brains that can navigate mazes, identify and catch falling objects, and work as a group to determine in which order they should ...

Facebook fends off telecom firms' complaints

1 hour ago

Facebook founder Mark Zuckerberg fended off complaints on Monday that the hugely popular social network was getting a free ride out of telecom operators who host its service on smartphones.

Scientists find clues to cancer drug failure

1 hour ago

Cancer patients fear the possibility that one day their cells might start rendering many different chemotherapy regimens ineffective. This phenomenon, called multidrug resistance, leads to tumors that defy ...

Glass coating improves battery performance

1 hour ago

Lithium-sulfur batteries have been a hot topic in battery research because of their ability to produce up to 10 times more energy than conventional batteries, which means they hold great promise for applications ...

Recommended for you

FDA warning: men's testosterone drugs overused (Update)

2 hours ago

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

Early benefit assessment increases transparency for study data

6 hours ago

Four years have passed since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG). AMNOG was primarily aimed at containing the increasing drug expenditure of the statutory health insurance ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.